Assertio Holdings (ASRT) EBITDA Margin (2019 - 2026)
Assertio Holdings' (ASRT) quarterly EBITDA Margin came in at 184.94% in Q1 2026, down 13536.0% year-on-year from N/an in Q1 2025, and down 113.16% quarter-over-quarter from 86.76% in Q4 2025.
Assertio Holdings (ASRT) EBITDA Margin (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed EBITDA Margin across 8 years of filings, most recently posting 184.94% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 184.94%, down 13536.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 25.92% (up 179.0% YoY), and the FY2025 annual result was 18.06%, up 137.0% from the prior year.
- EBITDA Margin came in at 184.94% for Q1 2026 at Assertio Holdings, down from 86.76% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 175.87% in Q4 2022 to a low of 784.64% in Q3 2023.
- The 5-year median for EBITDA Margin is 11.3% (2024), against an average of 65.41%.
- Across the five-year window, EBITDA Margin plunged 79684 bps in 2023 and jumped 77455 bps in 2024, its largest moves.
- Assertio Holdings' EBITDA Margin stood at 175.87% in 2022, then plunged by 199 bps to 173.97% in 2023, then soared by 76 bps to 41.56% in 2024, then plunged by 109 bps to 86.76% in 2025, then sank by 113 bps to 184.94% in 2026.
- The last three EBITDA Margin figures came in at 184.94% (Q1 2026), 86.76% (Q4 2025), and 23.41% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | -184.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -184.94% |
| Dec 31, 2025 | -86.76% |
| Sep 30, 2025 | 23.41% |
| Jun 30, 2025 | -27.15% |
| Mar 31, 2025 | -49.58% |
| Dec 31, 2024 | -41.56% |
| Sep 30, 2024 | -10.09% |
| Jun 30, 2024 | -11.30% |
| Mar 31, 2024 | -13.06% |
| Dec 31, 2023 | -173.97% |
| Sep 30, 2023 | -784.64% |
| Jun 30, 2023 | 20.66% |
| Mar 31, 2023 | -8.20% |
| Dec 31, 2022 | 175.87% |
| Sep 30, 2022 | 12.20% |
| Jun 30, 2022 | 22.30% |
| Mar 31, 2022 | 24.81% |
| Dec 31, 2021 | 13.82% |
| Sep 30, 2021 | 14.67% |
| Jun 30, 2021 | -55.84% |